Results 221 to 230 of about 4,942 (259)

Inclisiran – a new era in lipid-lowering therapy

Kardiologiia, 2022
Inclisiran is a novel hypolipidemic drug that inhibits synthesis of the PCSK9 protein through the process called RNA interference. Inclisiran is a double-stranded, modified RNA bound to the N-acetylgalactosamine (GalNAc) carbohydrate molecule, a ligand of the acialoglycoprotein receptor, that is expressed by hepatocytes.
M. I. Voevoda, V. S. Gurevich, M. V. Ezhov, I. V. Sergienko   +3 more
openaire   +2 more sources

Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.

Journal of clinical lipidology, 2022
Despite the development of new therapies to lower cardiovascular disease (CVD) risk in recent decades, the trend of reductions in CVD mortality has reversed. New therapies are essential for the prevention of first and recurrent CVD. The importance of lowering low-density lipoprotein cholesterol (LDL-C) in the management and prevention of ...
Daniel, Soffer, Robert, Stoekenbroek, Roda, Plakogiannis   +2 more
openaire   +1 more source

No meaningful cardiovascular outcome data for inclisiran

Drug and Therapeutics Bulletin, 2023
Abstract Overview of: Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J 2023;44:129–38.
openaire   +2 more sources

Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.

European Heart Journal
BACKGROUND AND AIMS Low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular (CV) disease development and progression.
Ulf Landmesser, U. Laufs, U. Schatz, E. Winzer, Bernd Nowak, U. Kassner, I. Gouni-Berthold, Alicia Esteban, Lawrence Lubyayi, Andre Krueger, Christian Hentschke, Andreas Wilke, Bernhard R Winkelmann, Assya Achouba, Maciej Banach   +14 more
semanticscholar   +1 more source

Adverse Events Associated with Inclisiran: A Real-world pharmacovigilance study of FDA adverse event reporting system (FAERS).

Expert Opinion on Drug Safety
OBJECTIVE To gain an improved comprehension of inclisiran safety in real-world settings by data mining from the US Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS).
Bing Li, Yan Chen, Yongyi Zhang, Mengying Qian, Qing Shan, Jiao Qian, Jinmin Guo   +6 more
semanticscholar   +1 more source

Inclisiran (Leqvio)

Canadian Journal of Health Technologies
CADTH recommends that Leqvio not be reimbursed by public drug plans as an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) levels in adults who are on a maximally tolerated dose (MTD) of a statin, with or without other LDL-C–lowering therapies, and who have nonfamilial hypercholesterolemia ...
openaire   +2 more sources

The Safety Profile of Inclisiran in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis

Healthcare
Introduction: Inclisiran is a novel drug that employs ribonucleic acid (RNA) interference to lower the levels of the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.
Maisha Maliha, Vikyath Satish, S. S. Kumar, K. Chi, Nishat Shama, Amrin Kharawala, Gustavo Duarte, Weijia Li, Sutopu Purkayastha, Shaunak Mangeshkar, Pawel Borkowski, Eleonora Gashi, Supreeti Behuria   +12 more
semanticscholar   +1 more source

Inclisiran patient experiences survey

European Journal of Cardiovascular Nursing
Abstract Introduction Inclisiran is a small interfering ribonucleic acid (siRNA), which increases LDL-C receptor recycling with a projected reduction of 50% in LDL-C. It is a twice a year injectable, licensed in the UK in January 2021.
A Barrowcliff, E Ikongo, M Khan, R Khatib   +3 more
openaire   +1 more source

Inclisiran

Journal of the American College of Cardiology, 2023
Christie M. Ballantyne, Abdul Mannan Khan Minhas, Carl E. Orringer   +2 more
openaire   +1 more source

Efficacy and safety of inclisiran based on background lipid-lowering treatment.

European Journal of Preventive Cardiology
AIM To evaluate whether the effect of inclisiran to lower LDL-C varied by background lipid-lowering therapy (LLT). METHODS In ORION-10 and ORION-11 Phase 3 trials, patients (N=3178) with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk ...
U. Landmesser, Wolfgang Koenig, L. A. Leiter, F. Raal, Kausik K. Ray, Gregory G. Schwartz, Jackie Han, L. G. Conde, R. S. Wright   +8 more
semanticscholar   +1 more source